• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers.

作者信息

Nitsche V, Mascher H

出版信息

Epilepsia. 1982 Apr;23(2):153-62. doi: 10.1111/j.1528-1157.1982.tb05063.x.

DOI:10.1111/j.1528-1157.1982.tb05063.x
PMID:6804223
Abstract

The pharmacokinetics of valproic acid were investigated in six healthy volunteers. After a single intravenous dose of 1,000 mg valproic acid, the pharmacokinetic parameters were determined according to the open two-compartment model. Bioavailability of valproic acid was performed comparing the areas under curves (AUC) after i.v and an equal single oral dose. The half-life of the initial phase was t 1/2 alpha = 0.64 +/- 0.32 h, and the elimination half-life was calculated as t 1/2 beta = 11.55 +/- 2.33 h. The distribution volume of the central compartment was Vc = 9.9 +/- 0.78 L, the apparent volume of distribution was Vd beta = 18.2 +/- 6.2 L, and the distribution volume at steady state was Vss = 12.6 +/- 1.2 L. The value for the average total clearance was Cltot = 51.1 +/- 11.9 ml/min. The study showed that in comparison to single dosing, the elimination half-life increased in average for four hours after multiple dosing (p less than or equal to 0.05). There was only a poor correlation between serum concentrations and concentration of valproic acid in saliva (r = 0.42).

摘要

相似文献

1
The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers.
Epilepsia. 1982 Apr;23(2):153-62. doi: 10.1111/j.1528-1157.1982.tb05063.x.
2
First-dose and steady-state pharmacokinetics of valproic acid in children with seizures.
Clin Pharmacokinet. 1983 Sep-Oct;8(5):447-55. doi: 10.2165/00003088-198308050-00005.
3
Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.外周作用的儿茶酚-O-甲基转移酶抑制剂恩他卡朋在人体中的药代动力学。一项使用稳定同位素技术的研究。
Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):821-6. doi: 10.1007/s002280000244.
4
Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.三种丙戊酸口服制剂给予人体后的药代动力学。
Isr J Med Sci. 1984 Jan;20(1):46-9.
5
A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.一项单剂量、三周期、六序列交叉研究,比较了空腹条件下健康墨西哥志愿者中镁丙戊酸盐溶液、混悬液和肠溶片剂的生物利用度。
Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016.
6
Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.曲马多的药代动力学及肠内曲马多制剂的生物利用度。第二次通讯:含乙醇滴剂
Arzneimittelforschung. 1998 May;48(5):436-45.
7
Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults.三种口服制剂在健康成年人中给药后丙戊酸的药代动力学。
J Assoc Physicians India. 1990 Sep;38(9):629-30.
8
Disposition of valproic acid in man.丙戊酸在人体内的处置。
Eur J Clin Pharmacol. 1977 Oct 14;12(2):125-32. doi: 10.1007/BF00645133.
9
Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.癫痫患者中稳态佐尼沙胺与丙戊酸之间不存在药代动力学相互作用。
Clin Pharmacokinet. 2005;44(5):517-23. doi: 10.2165/00003088-200544050-00005.
10
Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent.新型抗炎药托芬那酸的人体药代动力学
Eur J Clin Pharmacol. 1981;19(5):359-65. doi: 10.1007/BF00544587.

引用本文的文献

1
Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia.基于生理学的丙戊酸总浓度和游离浓度的药代动力学模型,用于评估低白蛋白血症儿童和非低白蛋白血症儿童的给药剂量。
Clin Pharmacokinet. 2024 Oct;63(10):1435-1448. doi: 10.1007/s40262-024-01418-8. Epub 2024 Sep 19.
2
Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact.基于生理学的机制洞察:丙戊酸致肝毒性在儿童和成人之间的差异风险:重点关注个体发育的影响。
CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1960-1971. doi: 10.1002/psp4.13045. Epub 2023 Oct 11.
3
The Effect of Plasma Protein Binding on the Therapeutic Monitoring of Antiseizure Medications.
血浆蛋白结合对抗癫痫药物治疗监测的影响。
Pharmaceutics. 2021 Aug 5;13(8):1208. doi: 10.3390/pharmaceutics13081208.
4
Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.使用唾液进行抗癫痫药物治疗药物监测的可行性
Eur J Drug Metab Pharmacokinet. 2021 Mar;46(2):205-223. doi: 10.1007/s13318-020-00661-1.
5
A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.一个考虑蛋白质结合作用的丙戊酸缓释颗粒制剂在癫痫患儿中的群体药代动力学模型。
Eur J Clin Pharmacol. 2018 Jun;74(6):793-803. doi: 10.1007/s00228-018-2444-2. Epub 2018 Mar 21.
6
Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.基于生理学的丙戊酸和丙戊酸钠处置及药物相互作用的药代动力学模型。
Eur J Pharm Sci. 2018 Jan 1;111:465-481. doi: 10.1016/j.ejps.2017.10.009. Epub 2017 Oct 10.
7
Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.使用唾液样本进行治疗药物浓度监测。重点关注抗惊厥药。
Clin Pharmacokinet. 1999 Jun;36(6):453-70. doi: 10.2165/00003088-199936060-00006.
8
Therapeutic drug monitoring--antiepileptic drugs.治疗药物监测——抗癫痫药物
Br J Clin Pharmacol. 1998 Sep;46(3):185-93. doi: 10.1046/j.1365-2125.1998.00769.x.
9
Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.老年患者的抗惊厥治疗。临床药代动力学考量
Drugs Aging. 1997 Apr;10(4):278-89. doi: 10.2165/00002512-199710040-00004.
10
Rectal administration of sodium valproate in children.
Ital J Neurol Sci. 1984 Jun;5(2):189-93. doi: 10.1007/BF02043222.